Radiopharmaceuticals

Challenge A private equity fund which had successfully invested in the advanced biologics CDMO space was considering entering the radiopharmaceuticals CDMO space through investment in an established...

Challenge A radiopharmaceuticals CDMO with activities in a range of therapeutic and diagnostic compounds including development-stage and commercial products asked Alacrita to assess the landscape and...

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...

Challenge A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that...

Challenge A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.